Challenges and risks of using GLP-1 antagonists in treating type 2 diabetes and obesity

Introduction: Ozempic (semaglutide) is a long-acting GLP-1 receptor agonist widely used to treat type II diabetes and obesity. Its mechanism of action includes stimulation of insulin secretion, inhibition of glucagon secretion, and delaying gastric emptying, which leads to lower blood glucose level...

Full description

Bibliographic Details

Published in:	Quality in Sport
Main Authors:	Agnieszka Głuszczyk, Jakub Plizga, Aleksandra Makłowicz, Ewelina Kopczyńska, Angelika Szpulak, Agata Frańczuk, Michalina Grzelka, Julia Głoskowska, Katarzyna Kuleta, Patrycja Karkos
Format:	Article
Language:	English
Published:	Nicolaus Copernicus University in Toruń 2024-08-01
Subjects:	ozempic ozempic face semaglutide GLP-1 obesity
Online Access:	https://apcz.umk.pl/QS/article/view/53683